Oklahoma Senate Bill SB34

Oklahoma 2026 Regular Session

• Introduced: 2/3/25
• Refer: 2/4/25

Caption

Prescription drugs; creating the Access to Lifesaving Medicines Act; prohibiting certain costs and requiring rebates under certain plans. Effective date.

Summary

SB34, the “Access to Lifesaving Medicines Act,” would add a new section to Oklahoma insurance law governing prescription drug cost-sharing in health benefit plans. The bill defines a set of terms related to drug pricing, rebates, pharmacy benefits managers (PBMs), and point-of-sale transactions, then prohibits health insurers and PBMs from imposing an “excess cost burden” on insureds for covered prescription drugs. It also requires PBMs, when contracting to administer pharmacy benefits, to offer health plans the option of passing rebates through to enrollees at the point of sale. The bill further establishes that an insured’s prescription drug cost-sharing must be the lowest of several measures, including the plan copayment, maximum allowable cost, maximum allowable claim, adjusted out-of-pocket amount, the cash price without insurance, or the amount the pharmacy is reimbursed. The Insurance Commissioner would be directed to adopt rules to implement the new requirements, and the act would take effect November 1, 2025.

Impact

SB34 would amend Title 36 of the Oklahoma Statutes by creating Section 6970 and imposing new requirements on health insurers and pharmacy benefits managers that provide prescription drug coverage. It would affect how covered drug costs are calculated at the point of sale, potentially lowering out-of-pocket costs for insured consumers and changing reimbursement and rebate practices for insurers, PBMs, and pharmacies. The bill also gives the Insurance Commissioner rulemaking authority to carry out the law’s provisions.

Sentiment

The available context suggests the bill is framed positively as a consumer-cost relief measure, with its title and structure emphasizing access to medicines and limits on prescription drug cost-sharing. There are no recorded committee transcripts or votes in the provided material, so there is no direct evidence of debate, support, or opposition in committee or on the floor. Based on the text alone, the bill appears intended to address affordability concerns in prescription drug coverage.

Contention

The main likely point of contention is the bill’s restriction on insurer and PBM pricing practices, especially the requirement to avoid excess cost burdens and the option to extend point-of-sale rebates to enrollees. Insurers and PBMs may view these provisions as limiting their flexibility in benefit design, rebate retention, and reimbursement arrangements, while consumer advocates and insured patients would likely favor the lower out-of-pocket costs. Another possible issue is the administrative complexity of determining the lowest applicable cost-sharing amount and implementing new rules across health plans and pharmacies.